Okupe Oluyemi, Chief Financial Officer of Hims & Hers Health (HIMS), has demonstrated a clear selling bias in recent transactions, with no open-market purchases recorded in the past year. SEC Form 4 filings reveal $32.9 million in total sales against just $1.5 million in buys across 55 transactions, all concentrated in HIMS stock. The most significant disposals occurred on March 13, 2026, when Oluyemi executed two large sales: a $5.6 million transaction coded as a derivative disposition (F) and a separate $1.43 million derivative sale the same day. These followed earlier sales including an $824,710 open-market disposal on December 22, 2025, and multiple six-figure sales in early 2026—$306,453 on January 5, $275,114 on January 20, and $139,108 on February 3.
The pattern intensified in March 2026, with Oluyemi liquidating an additional $219,067 worth of shares on March 20 alongside smaller derivative transactions. Notably, all recent activity involved sales or derivative dispositions, with zero buy transactions since at least December 2025. The transactions suggest a consistent reduction in exposure to HIMS stock, with the largest disposals occurring through derivative instruments rather than open-market sales. While the filings don't indicate the reasons for these transactions, the data reflects a sustained directional trend favoring divestment over accumulation in Oluyemi's holdings of company stock.
AI-assisted summary